ADTX - Aditxt, Inc.
After hours:
| Previous close | 0.5999 |
| Open | 0.6094 |
| Bid | 0.5900 x 4000 |
| Ask | 0.6000 x 1400 |
| Day's range | 0.5900 - 0.6094 |
| 52-week range | 0.5500 - 28.4900 |
| Volume | |
| Avg. volume | 747,625 |
| Market cap | 4.056M |
| Beta (5Y monthly) | 1.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.6900 |
| Earnings date | 13 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
Business WireAditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
RICHMOND, Va., May 05, 2023--Aditxt®, Inc. announces that its subsidiary Adimune,™ Inc. has signed a clinical trial agreement with Mayo Clinic to study Stiff Person Syndrome.
- Business Wire
Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
RICHMOND, Va., April 24, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price o
- Business Wire
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
RICHMOND, Va., April 20, 2023--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.22 per share (o
- Business Wire
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
RICHMOND, Va., April 20, 2023--Aditxt,® Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an asset purchase agreement with Cellvera, Ltd. ("Cellvera") that grants Aditxt (whether directly or in its recently formed wholly owned subsidiary Adivir, ™ Inc. ("Adivir"), a 50% ownership in G Response Aid FZE ("GRA" or "Global Response Aid") with the othe
Business WireAditxt Issues Shareholder Update
RICHMOND, Va, April 17, 2023--Aditxt,® Inc, (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its three innovation programs and strategic M&A initiatives.
- Business Wire
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer
RICHMOND, Va., March 08, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is pleased to announce Maureen Connolly has joined Aditxt as Chief Content and Engagement Officer. Connolly is an award-winning content strategist and audience builder with 25+ years of experience in the health, science, wellness, technology, and chronic conditions space. She works w
- Business Wire
Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.
RICHMOND, Va., March 03, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has retained Riverside Management Group, LLC ("Riverside Management Group" or "RMG"), a merchant banking firm providing investment banking advisory services, to support the Company’s ongoing growth and revenue generating plans for its subsidiary Pearsanta, Inc. ("P
- Business Wire
Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President
RICHMOND, Va., February 14, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. ("Pearsanta"), to accelerate the growth of Aditxt’s second program, AditxtScore™, through future strategic revenue and growth-oriented transactions.
ZacksIs the Options Market Predicting a Spike in Aditx (ADTX) Stock?
Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
- Business Wire
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
RICHMOND, Va., January 03, 2023--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request a
ZacksImplied Volatility Surging for Aditx Therapeutics (ADTX) Stock Options
Investors need to pay close attention to Aditx Therapeutics (ADTX) stock based on the movements in the options market lately.
- Business Wire
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
RICHMOND, Va., October 21, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces that its program Adimune™ has initiated the GMP manufacturing of drug candidate ADI™-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023. Pending regulatory approvals, these trials will be performed in autoimmun
- Business Wire
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
RICHMOND, Va., October 12, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology.
- Business Wire
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health
RICHMOND, Va., October 07, 2022--Aditxt, Inc.’s (NASDAQ: ADTX) ("Aditxt", or the "Company") AditxtScore™ is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19.
- Business Wire
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements
RICHMOND, Va., September 29, 2022--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel ("Nasdaq") that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), meets the stockholders’ equity requirement
- Business Wire
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
RICHMOND, Va., September 27, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today provides shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering.
- Business Wire
Aditxt Announces Closing of $20.0 Million Public Offering
RICHMOND, Va., September 20, 2022--Aditxt, Inc., (Nasdaq: ADTX) (the "Company" or "Aditxt"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the closing of its previously announced public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the publi
- Business Wire
Aditxt Announces Pricing of $20.0 Million Public Offering
RICHMOND, Va., September 16, 2022--Aditxt, Inc., (Nasdaq: ADTX) (the "Company" or "Aditxt"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the pricing of a public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share (o
- Business Wire
Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
RICHMOND, Va., September 13, 2022--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on September 13, 2022. Commencing with the opening of trading on The Nasdaq Capital Market on September 14, 2022, the Company’s common stock will trade on a post-split basis under the sam
- Business Wire
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials
RICHMOND, Va., July 08, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseas